We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Warns Compounding Pharmacy for Lax Aseptic Processing

FDA Warns Compounding Pharmacy for Lax Aseptic Processing

August 15, 2014

The FDA delivered its fifth warning letter to a compounding pharmacy in roughly two weeks, admonishing a Texas compounder for poor aseptic processing of sterile drugs.
The letter chides Abrams Royal Pharmacy for numerous quality violations uncovered during a December 2013 inspection of its Dallas, Texas, compounding facility.

Chief among them was the use of non-sterile gowns and gloves that exposed the wrists and nose. Employees were observed picking up items off the floor and continuing to process drugs without changing gloves or sanitizing their hands, said the July 14 letter.

In addition, Abrams failed to demonstrate that its hoods used in the clean room adequately protect sterile drugs from contamination, and employees didn’t use a sporicidal cleaning agent to disinfect the clean room, the letter said.

Abrams also compounded drugs without a prescription, a common finding in agency enforcement of large compounding pharmacies.

The compounder recalled all of its sterile products and agreed to cease production of sterile drugs following the December inspection. To resume operations, Abrams must meet good manufacturing practices for drug manufacturing, the FDA said. The company also should hire a third-party consultant with expertise in sterile drug manufacturing to assist with a comprehensive evaluation of its operations, the letter added.

The FDA also took the unusual step of ensuring that Abrams check the quality of its contractors. The compounder hired an unnamed contract testing laboratory to perform required testing on finished drug products, however the lab was cited by the FDA in 2012 and 2013 for serious GMP violations, the letter said.

The compounder warning is the latest signal that the agency intends to make full use of its new oversight powers granted under a November 2013 law. Abrams did not return a request for comment as of press time.

Make sure you meet good manufacturing practices for drug manufacturing. Train your staff on GMP’s the easy way with the Drug GMP Training Course: A 17-Module Customizable Training Series.

Pharmaceuticals Quality GMPs Inspections and Audits

Upcoming Events

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

  • 10Aug

    Gene & Cell Therapy Regulation: Comparability and Other New Developments

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators

  • Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter

  • FDA Warns Baby Neck Floats Used in Water Therapy Can Cause Death or Injury

  • U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing